Alaunos Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $4.7M
- Price
- $1.76
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.89%
- Volume
- 16.1K
About
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Quick stats
Shares outstanding2.4M
Computed float2.1M
Float / shares85.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001107421
Websitehttps://www.alaunos.com
AI Summary
AI-generated1/6
minorbullishoperations update
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study
Alaunos Therapeutics announced new preclinical data for its metabolic candidate ALN1003, showing lower liver weight in diet-induced obese mice after adjustment for body fat percentage.
The statistical analysis confirmed the findings with high significance (p=0.000005) and aligned with previous reductions in liver injury enzymes and HOMA-IR biomarkers.
The company disclosed a cash position of approximately $354,000 as of March 31, 2026, noting it intends to pursue additional financing to support operations.
Red flags
- Cash position of approximately $354,000 as of March 31, 2026 indicates severe liquidity constraints
- Findings are based on non-GLP preclinical studies with limited sample sizes
- ALN1003 has not been evaluated in human clinical trials